Department of Breast Surgery, Jilin Cancer Hospital, Changchun, Jilin Province, China.
Eur Rev Med Pharmacol Sci. 2017 Sep;21(18):4129-4136.
To analyze the functioning mode of miR-645 on breast cancer cell metastasis and provide therapeutic targets for breast cancer.
Quantitative Real-time PCR (qRT-PCR) assay was employed to detect miR-645 expression level. Wound healing assay and transwell assay were performed to investigate metastasis capacity of breast cancer cells. Protein levels were assessed by Western blotting assay. The target gene was predicted and verified by bioinformatics analysis and luciferase assay.
MiR-645 was upregulated in breast cancer tissues when compared with pericarcinous tissues (n=60). Downregulated miR-645 could attenuate breast cancer cell migration and invasion capacities, as well as inhibit the process of epithelial-mesenchymal transition (EMT). DCDC2 was chosen as the target gene of miR-645 by bioinformatic analysis and Luciferase reporter assay. Moreover, the silence of DCDC2 could rescue tumor suppression role of downregulated miR-645 on breast cancer metastasis.
Knockdown of miR-645 exerted tumor-suppressive effects on breast cancer metastasis via targeting DCDC2 in vitro, which provided an innovative and candidate target for diagnose and treatment of breast cancer.
分析 miR-645 对乳腺癌细胞转移的作用模式，为乳腺癌提供治疗靶点。
采用实时定量 PCR（qRT-PCR）检测 miR-645 的表达水平。通过划痕愈合实验和 Transwell 实验检测乳腺癌细胞的转移能力。采用 Western blot 检测蛋白水平。通过生物信息学分析和荧光素酶报告实验预测和验证靶基因。
与癌旁组织（n=60）相比，miR-645 在乳腺癌组织中呈上调表达。下调 miR-645 可减弱乳腺癌细胞的迁移和侵袭能力，并抑制上皮-间充质转化（EMT）过程。生物信息学分析和荧光素酶报告实验选择 DCDC2 作为 miR-645 的靶基因。此外，沉默 DCDC2 可挽救下调 miR-645 对乳腺癌转移的肿瘤抑制作用。
在体外，下调 miR-645 通过靶向 DCDC2 对乳腺癌转移发挥肿瘤抑制作用，为乳腺癌的诊断和治疗提供了新的候选靶点。
